- Home
- GLTO vs FTFT Comparison
GLTO vs FTFT Comparison
Compare GLTO & FTFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- FTFT
- Stock Information
- Founded
- GLTO 2011
- FTFT N/A
- Country
- GLTO Denmark
- FTFT United States
- Employees
- GLTO N/A
- FTFT N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- FTFT Business Services
- Sector
- GLTO Health Care
- FTFT Consumer Discretionary
- Exchange
- GLTO Nasdaq
- FTFT Nasdaq
- Market Cap
- GLTO 6.5M
- FTFT 6.2M
- IPO Year
- GLTO 2020
- FTFT N/A
- Fundamental
- Price
- GLTO $3.97
- FTFT $0.19
- Analyst Decision
- GLTO Buy
- FTFT
- Analyst Count
- GLTO 1
- FTFT 0
- Target Price
- GLTO $10.00
- FTFT N/A
- AVG Volume (30 Days)
- GLTO 16.9K
- FTFT 11.9M
- Earning Date
- GLTO 04-28-2025
- FTFT 04-15-2025
- Dividend Yield
- GLTO N/A
- FTFT N/A
- EPS Growth
- GLTO N/A
- FTFT N/A
- EPS
- GLTO N/A
- FTFT N/A
- Revenue
- GLTO N/A
- FTFT $18,543,659.00
- Revenue This Year
- GLTO N/A
- FTFT N/A
- Revenue Next Year
- GLTO N/A
- FTFT N/A
- P/E Ratio
- GLTO N/A
- FTFT N/A
- Revenue Growth
- GLTO N/A
- FTFT N/A
- 52 Week Low
- GLTO $3.76
- FTFT $0.18
- 52 Week High
- GLTO $21.05
- FTFT $1.21
- Technical
- Relative Strength Index (RSI)
- GLTO 37.21
- FTFT 40.23
- Support Level
- GLTO $3.84
- FTFT $0.20
- Resistance Level
- GLTO $4.38
- FTFT $0.25
- Average True Range (ATR)
- GLTO 0.28
- FTFT 0.04
- MACD
- GLTO -0.02
- FTFT 0.00
- Stochastic Oscillator
- GLTO 23.15
- FTFT 6.81
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About FTFT Future FinTech Group Inc.
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and cryptocurrency mining farm in the U.S. The company's reportable segments include the Supply chain financing/trading segment which generates key revenue, and the Asset management service segment.